AGTC - Applied Genetic Technologies Should Be On Your Radar After Latest Rare Disease Eye Data

Applied Genetic Technologies Corporation (AGTC) closed higher on Thursday by 123% to $9.27 per share, after it had announced a positive update from its phase 1/2 study using its gene therapy to treat patients with x-linked retinitis pigmentosa. The main thing is that this newly reported data, along with prior data, will allow the biotech to initiate a phase 3 study for this patient population by the end of 2020. On top of that, there is a catalyst opportunity expected at the end of this month. This will be the release of updated

Read more ...